Digital Therapeutics Alliance Appoints MedRhythms Co-Founder Owen McCarthy to Chair Board of Directors
Digital Therapeutics Alliance ("DTA" or "Alliance"), a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics (DTx) into healthcare, today announced the appointment of Owen McCarthy, Co-Founder & President, MedRhythms, to Chair its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005012/en/
"Owen's depth of knowledge in bringing novel digital therapeutics to market will provide invaluable expertise to the DTA member network," said Andy Molnar, CEO, Digital Therapeutics Alliance. "I look forward to working with Owen to drive the industry forward and capitalize on the massive opportunity digital therapeutics can have to improve lives and health outcomes and streamline care."
"I look forward to working with Andy, the DTA team and Board members to advance the digital therapeutics industry," said Owen McCarthy, President & Co-Founder, MedRhythms and DTA Board Chairman. "The industry has a strong foundation and tremendous momentum to realize its full potential for the patients that our member companies strive to serve. At MedRhythms, we're advancing the first digital therapeutic to improve walking for patients with acute stroke, and we're excited to announce data from our pivotal study later this year."
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
MedRhythms is a digital therapeutics company that uses sensors, music and software to build evidence-based neurologic interventions to measure and improve walking. The company is developing a pipeline of digital therapeutics in neurological conditions such as Parkinson's, acute stroke and multiple sclerosis, including a neuroimaging study with Massachusetts General Hospital. MedRhythms has received FDA Breakthrough Device designation for its lead digital therapeutic to treat chronic stroke walking deficits. The company was founded out of Spaulding Rehabilitation Hospital, one of the leading rehabilitation hospitals in the United States. MedRhythms is headquartered in Portland, Maine. For more information, visit www.medrhythms.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005012/en/